Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Crossref DOI link: https://doi.org/10.1007/s40273-017-0497-1
Published Online: 2017-03-24
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Morgan, Philip http://orcid.org/0000-0002-7172-7480
Woolacott, Nerys
Biswas, Mousumi
Mebrahtu, Teumzghi
Harden, Melissa
Hodgson, Robert
Funding for this research was provided by:
Health Technology Assessment Programme (15/121/10)
License valid from 2017-03-24